- cafead Dec 07, 2020 at 11:12: AM
via J&J is trying something new for prostate cancer.
Teaming up with Xencor, its Janssen subsidiary is looking to discover bispecific antibodies that grab CD28 on one end and an undisclosed prostate tumor target on the other. The upfront comes in at $50 million.
article source
Teaming up with Xencor, its Janssen subsidiary is looking to discover bispecific antibodies that grab CD28 on one end and an undisclosed prostate tumor target on the other. The upfront comes in at $50 million.
article source